Lifestyle Features

Russia says no plague cases detected among contacts of deceased lab worker

Russia's health watchdog said on Tuesday that no cases of plague had been detected among people who had come into contact with a Siberian plague institute laboratory worker who died last week.

Russia says no plague cases detected among contacts of deceased lab worker

Most Recent

.js-only { display: none; } .queue_story .image_box:before, #loadMoreStories, .browseday { display: none; }

Kenya confirms first Ebola case imported from Congo

Kenya confirms first Ebola case imported from Congo

Reuters | Updated Oct. 6 - 4:00 a.m. | Save Story

Kenya confirmed its first Ebola case on Tuesday after a Kenyan citizen who had travelled from the Democratic Republic of Congo died in Nairobi.

Could your charging habits spark a fire? Safety tips from firefighters for Fire Prevention Week

Could your charging habits spark a fire? Safety tips from firefighters for Fire Prevention Week

VideoEmma Benson, KSL | Updated Oct. 5 - 9:37 p.m. | Save Story

Safe charging habits and proper battery disposal can help prevent fires involving everyday devices, firefighters say.

Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study

Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study

Sahil Pandey, Reuters | Updated Oct. 5 - 4:09 p.m. | Save Story

Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk ‌of disease progression or death in a late-stage study.

Dozens quarantined in Siberia after plague institute lab worker dies

Dozens quarantined in Siberia after plague institute lab worker dies

Andrew Osborn, Reuters | Updated Oct. 5 - 3:22 p.m. | Save Story

A laboratory worker at a plague research institute in Siberia fell ill and died in undisclosed circumstances, prompting authorities to quarantine dozens of people and the head of Russia's health watchdog to fly to the Irkutsk region.

McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports

McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports

Sahil Pandey, Reuters | Updated Oct. 5 - 3:08 p.m. | Save Story

Drug distributor McKesson and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued ‌at more than $5 billion including debt, the Financial Times reported on Monday, ⁠citing people familiar with the matter.

Pennsylvania measles cases rise to 1,004 as outbreak spreads

Pennsylvania measles cases rise to 1,004 as outbreak spreads

Reuters | Posted Oct. 5 - 12:52 p.m. | Save Story

Pennsylvania's health department reported 1,004 measles cases as of Monday, as the state grapples with a fast-growing outbreak.

US and German scientists win Nobel medicine prize for work on light and brain

US and German scientists win Nobel medicine prize for work on light and brain

Johan Ahlander, Marie Mannes and Bhanvi Satija, Reuters | Updated Oct. 5 - 11:20 a.m. | Save Story

American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine on Monday for developing optogenetics, a technique that uses light to control individual nerve cells in the brain.

Nightmare on 13th earns national Halloween recognition

Nightmare on 13th earns national Halloween recognition

VideoTyrese Boone, KSL | Posted Oct. 5 - 10:03 a.m. | Save Story

A Salt Lake City haunted attraction is getting national recognition as one of America Haunts' Top 5 Fan Favorites for 2026.

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Rajasik Mukherjee, Reuters | Updated Oct. 5 - 9:42 a.m. | Save Story

Australia's CSL said on Monday it had entered into an agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up ‌to $1.6 billion, excluding development funding.

Gate Bioscience expands Lilly drug discovery deal worth more than $870 million

Gate Bioscience expands Lilly drug discovery deal worth more than $870 million

Reuters | Updated Oct. 5 - 7:54 a.m. | Save Story

Gate Bioscience said on Monday it expanded a research and licensing agreement with Eli Lilly to develop treatments targeting ‌disease-causing proteins, in a deal potentially worth more than $870 ⁠million.

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Reuters | Updated Oct. 5 - 7:54 a.m. | Save Story

Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, the US biotech said on ‌Monday, sending its shares surging 72% in premarket trading.

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

Vaxcyte shares surge as pneumococcal vaccine succeeds in late-stage trial

Siddhi Mahatole, Reuters | Updated Oct. 5 - 7:44 a.m. | Save Story

Vaxcyte said on Monday its experimental pneumococcal vaccine generated immune responses comparable to rival vaccines in a late-stage study, sending its shares up 57% in morning trading.

Most Americans are comfortable with kids playing football. Then we told them about CTE

Most Americans are comfortable with kids playing football. Then we told them about CTE

Dennis Romboy, Deseret News | Posted Oct. 5 - 7:22 a.m. | Save Story

A majority of people across the country feel at ease with kids playing tackle football — until they figure out how much of an impact CTE could have later in their kids' lives.

GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business

GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business

Reuters | Updated Oct. 5 - 7:09 a.m. | Save Story

Medical device maker GE HealthCare said on Monday it would buy privately held Sofie Biosciences for $945 million in cash, in a move that strengthens its ability to manufacture ‌and distribute PET imaging drugs.

SNAP benefits look different starting now. What changed?

SNAP benefits look different starting now. What changed?

Lois M. Collins, Deseret News | Posted Oct. 3 - 9:12 p.m. | Save Story

Major changes to the Supplemental Nutrition Assistance Program took effect Thursday, but the biggest effects are expected to be seen in the future.

Destination restaurants worth traveling across the world for

Destination restaurants worth traveling across the world for

Chris Dwyer, CNN | Updated Oct. 3 - 7:06 p.m. | Save Story

Some meals begin long before the first plate is served, especially at these global eateries. Find out which ones are worth the money — and the travel.

Meet the air traffic controller who flies himself to work

Meet the air traffic controller who flies himself to work

Hallie Golden and Thomas Peipert, Associated Press | Updated Oct. 3 - 6:27 p.m. | Save Story

For someone who has been fascinated with flying since childhood, Jacob Hutzler has a particularly satisfying commute, calling it as close as you can get to flying like a bird.

How to support someone who's suicidal

How to support someone who's suicidal

Kristen Rogers, CNN | Posted Oct. 3 - 9:56 a.m. | Save Story

Despite increasing awareness about mental health, suicide is often still heavily stigmatized and therefore concealed in various ways.

AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination

AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination

Reuters | Updated Oct. 2 - 12:12 p.m. | Save Story

Summit Therapeutics on Friday announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to test their cancer drug Datroway in combination with Summit's ‌ivonescimab across multiple tumour types, including lung and breast cancers.